Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANTE study of treatment-free remission after first-line nilotinib in chronic myeloid leukemia
2018-002898-21Phase 2Active
- Sponsor
- Novartis
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoint: Full treatment-free remission at week 96. Started Jan 2021; status: active.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2018-002898-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002898-21.